PMKB
PMKB
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity
Login
KIT
Information
View History
Pending Review
Interpretation 2201
Tier 1
KIT
Variants
KIT V555_L576del
Primary Sites
Unknown
Tumor Types
Gastrointestinal Stromal Tumor
Interpretation
Sunitinib Imatinib Nilotinib
Citations
Blanke CD, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26(4):620-5
Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
Zalcberg JR, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41(12):1751-7
Reichardt P, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23(7):1680-7
Last updated: 2018-04-18 13:23:34 UTC
PMKB Bot
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity